11 Sunscreens Sold In New Zealand Didn't Meet SPF Claims, As Revealed By An Australian Test
Australian consumer group Choice's test of household sunscreens has shown 16 out of 20 tested sunscreens didn't meet their SPF claims.
These include products sold in New Zealand, including Banana Boat, Nivea and Neutrogena sunscreens.
Consumer NZ research and test writer Belinda Castles says consumers expect sunscreens to protect them. But Castles isn't surprised the protection falls short of what's claimed on the bottle.
'Consumer NZ ran a sunscreen testing programme until 2022, and the results found by Choice are consistent with what we've found previously,' she says.
The Choice test found:
Nivea Sun Protect & Moisture Lock SPF50+ tested at SPF40
Sun Bum Premium Moisturising Sunscreen Lotion SPF50+ tested at SPF40.
Consumer's 2021 tests of both these sunscreens also got SPF results in the 40s.
Banana Boat, Bondi Sands and Neutrogena sunscreens also failed to meet their SPF label claims in both Choice and earlier Consumer testing.
While most of the products in the Australian tests still provide moderate or high SPF protection, one product – Ultra Violette Lean Screen SPF50+ Mattifying Zinc Sunscreen – only returned an SPF of 4. Choice tested the sunscreen again at a second lab to confirm this result and got a similar low SPF of5. This sunscreen is also sold in New Zealand.
Castles says the test results for the big sunscreen brands is particularly concerning, given these companies' lack of transparency about when and where their products are tested.
'Sunscreens sold in New Zealand are now regulated under the Sunscreen (Product Safety Standard) Act 2022 and must meet the Australian and New Zealand sunscreen standard, which has requirements for independent testing. However, when we updated our sunscreens database last year, the companies that market Banana Boat, Bondi Sands, Neutrogena, Nivea and Sun Bum refused to provide this information.'
Consumer has also been campaigning for companies to be required to test their sunscreens regularly to ensure the products continue to meet their label claims.
'Our sunscreen research found some companies were relying on test results that are several years old. The latest Choice tests back our call.'
Invisible Zinc Face + Body Mineral Sunscreen SPF50+ tested at 38 in the Australian test. The company told Consumer this product was last tested in 2017.
Woolworths Sunscreen SPF50+ Everyday Lotion tested at 27 in the Australian test. The company told Consumer this product was last tested in 2018.
Choice is calling on Australia's Therapeutic Goods Administration to urgently carry out its own sunscreen compliance testing. Choice has also asked the Australian Competition and Consumer Commission (ACCC) to investigate if any SPF claims are misleading.
Consumer will be raising the same issues with New Zealand regulators and the Commerce Commission.
Products tested available in New Zealand
SPF results in 50+
La Roche-Posay Anthelios Wet Skin Sunscreen SPF 50+ – tested at 72
Neutrogena Ultra Sheer Body Lotion SPF 50 – tested at 56
Mecca Cosmetica To Save Body SPF 50+ Hydrating Sunscreen – tested at 51
SPF results in the 40s
Nivea Sun Kids Ultra Protect and Play Sunscreen Lotion SPF 50+ – tested at 41
Nivea Sun Protect and Moisture Lock SPF 50+ Sunscreen – tested at 40
Sun Bum Premium Moisturising Sunscreen Lotion 50+ – tested at 40
SPF results in the 30s
Banana Boat Sport Sunscreen Lotion SPF 50+ – tested at 35
Bondi Sands SPF 50+ Fragrance Free Sunscreen – tested at 32
Invisible Zinc Face + Body Mineral Sunscreen SPF 50 – tested at 38
SPF results in the 20s
Banana Boat Baby Zinc Sunscreen Lotion SPF 50+ – tested at 28
Bondi Sands SPF 50+ Zinc Mineral Body Lotion – tested at 26
Neutrogena Sheer Zinc Dry-Touch Lotion SPF 50 – tested at 24
Woolworths Sunscreen Everyday Tube SPF 50+ – tested at 27
SPF results <10
Ultra Violette's Lean Screen SPF 50+ Mattifying Zinc Skinscreen – tested at 4
For the full test results, visit CHOICE sunscreen results: https://www.choice.com.au/health-and-body/beauty-and-personal-care/skin-care-and-cosmetics/articles/sunscreen-test
In partnership with Health New Zealand Te Whatu Ora, Consumer NZ's sunscreen database allows users to filter sunscreens by factors such as price, water resistance, SPF protection and the last time a sunscreen was tested.
For more information about sunscreens, including information about the 150+ sunscreens in our database, visit: Sunscreens | Overview - Consumer NZ: https://www.consumer.org.nz/products/sunscreens
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Otago Daily Times
7 hours ago
- Otago Daily Times
Relax, and think of your skin
Yes, a hot bath feels lovely, but there are things you need to watch, write Amanda Meyer and Monika Zimanyi. The weather is getting cooler and many of us are turning to hot showers and baths to warm up and wind down. But what actually happens to your skin when you have really hot showers or baths? YOUR LARGEST ORGAN Your skin is your largest organ, and has two distinct parts: the epidermis on the outside, and the dermis on the inside. The epidermis is made up of billions of cells that lay in four layers in thin skin (such as on your eyelids) and five layers in thick skin (such as the on sole of your foot). The cells (keratinocytes) in the deeper layers are held together by tight junctions. These cellular bridges make waterproof joins between neighbouring cells. The cells on the outside of the epidermis have lost these cellular bridges and slough off at a rate of about 1000 cells per one centimetre squared of skin per hour. For an average adult, that's 17 million cells per hour, every day. Under the epidermis is the dermis, where we have blood vessels, nerves, hair follicles, pain receptors, pressure receptors and sweat glands. Together, the epidermis and dermis (the skin): • protect you from ultraviolet radiation from the Sun • synthesise vitamin D3, which helps your intestines absorb calcium • protect you against bacteria, parasites, fungi and viruses • regulate your body temperature via the dilation of blood vessels and sweat glands releasing sweat • help display how we're feeling (think, for example, of blushing or goosebumps) • allow us to feel sensations such as touch, pressure, pain and temperature. So, your skin is important and worth looking after. Washing daily can help prevent disease, and really hot baths often feel lovely and can help you relax. That said, there are some potential downsides. THE SKIN MICROBIOTA Normally we have lots of healthy organisms called Staphyloccocus epidermis on the skin. These help increase the integrity of our skin layers (they make the bonds between cells stronger) and stimulate production of anti-microbial proteins. These little critters like an acidic environment, such as the skin's normal pH of between 4-6. If the skin pH increases to about 7 (neutral), Staphyloccocus epidermis' nasty cousin Staphyloccocus aureus — also known as golden staph — will try to take over and cause infections. Having a hot shower or bath can increase your skin's pH, which may ultimately benefit golden staph. Being immersed in really hot water also pulls a lot of moisture from your dermis, and makes you lose water via sweat. This makes your skin drier, and causes your kidneys to excrete more water, making more urine. Staying in a hot bath for a long time can reduce your blood pressure, but increase your heart rate. People with low blood pressure or heart problems should speak to their doctor before having a long hot shower or bath. Heat from the shower or bath can activate the release of cytokines (inflammatory molecules), histamines (which are involved in allergic reactions), and increase the number of sensory nerves. All of this can lead to itchiness after a very hot shower or bath. Some people can get hives (itchy raised bumps that look red on lighter skin and brown or purple on darker skin) after hot showers or baths, which is a form of chronic inducible urticaria. It's fairly rare and is usually managed with antihistamines. People with sensitive skin or chronic skin conditions such as urticaria, dermatitis, eczema, rosacea, psoriasis or acne should avoid really hot showers or baths. They dry out the skin and leave these people more prone to flare ups. MAKING THE MOST OF MOISTURISING Moisturising after a hot bath or shower can help, but check if your moisturiser is up to the task. To improve the skin barrier, your moisturiser needs to contain a mix of: • an emollient such as ceramides, squalanes or dimethicone (emollients incorporate themselves into the lipid barrier in the epidermis to reduce water loss) • a humectant such as glycerin or hyaluronic acid (humectants draw moisture from the dermis into the epidermis) • an occlusive such as petroleum jelly or Vaseline, mineral oil, or cocoa butter (occlusives reduce water loss through the skin and increase the production of anti-microbial peptides). Not all moisturisers are actually good at reducing the moisture loss from your skin. You still might experience dryness and itchiness as your skin recovers if you've been having a lot of really hot showers and baths. Amanda Meyer is a senior lecturer, anatomy and pathology in the College of Medicine and Dentistry, and Monika Zimanyi is an associate professor in anatomy, at James Cook University.
Scoop
a day ago
- Scoop
Tonga's Health System Hit By Cyberattack
A team of Australian cyber experts flew to Tonga this week after the country's National Health Information System was breached, leading to a demand for payment from the hackers. Talanoa O Tonga reports the Health Minister Dr Ana Akauola saying the system has been shut down, and staff are handling data manually. Dr Akauola said that hackers encrypted the system and demanded payment, but she has assured MPs "the hackers won't damage the information" on the system. This system was introduced in 2019 with Asian Development Bank (ADB) support to digitise Tonga's health records before going "live" in 2021. Police Minister Paula Piukala was critical of past governments for ignoring warnings that Tonga's digital infrastructure is not fully prepared for these threats. Journalist Sifa Pomana said the hackers are demanding millions of dollars, according to Tonga Police. Residents are being urged to bring essential records to the hospital to help with manual record-keeping.
Scoop
5 days ago
- Scoop
Australasian-led Clinical Trial In Stem Cell Transplant For Blood Cancers Set To Change 40 Years Of Standard Practice
Leading Australian and New Zealand researchers have demonstrated that the use of a new, less toxic drug combination after stem cell transplants for leukaemia significantly improves patient outcomes post-transplant, reducing the risk of the life-threatening complication of Graft Versus Host Disease (GVHD). The BM12 CAST trial, a major clinical trial led by the Australasian Leukaemia & Lymphoma Group (ALLG) across New Zealand and Australian hospitals, will transform global blood stem cell transplant outcomes for people with high-risk blood cancers like leukaemia. 'This new treatment triples the chances of a patient being alive, healthy and free of GVHD three years after stem cell transplant,' said lead ALLG BM12 researcher, Professor David Curtis, Clinical Haematologist and senior bone marrow transplant physician at The Alfred and Director of Malignant Haematology Research at the Australian Centre for Blood Diseases, Monash University. Blood stem cell transplants are often lifesaving for leukaemia patients, but they come with a high risk of life-threatening complications, especially in the first 100 days after transplant. Common side effects include infections, organ damage, and the often-debilitating Graft versus Host Disease (GVHD), an irreversible lifelong complication. 'The BM12 trial showed the new treatment combination is simple, safe and more effective than current methods in preventing GVHD, which contributes to death or life-long illness in 20% of patients undergoing a blood stem cell transplant,' said Prof Curtis. Results of BM12 trial were published in the New England Journal of Medicine and presented at the European Hematology Association 2025 Meeting in Milan, Italy. These results are game-changing for stem cell transplant patients, with cyclosporin and cyclophosphamide offering a new standard of care for prevention of GVHD for patients with aggressive blood cancers undergoing transplant from a matched related blood stem cell donor. Researchers compared the standard drug combination used for the last 40 years with a new combination of cyclophosphamide and cyclosporin, for leukaemia patients. The new drug combination tripled the number of patients that were alive, cured of the blood cancer and not suffering from GVHD three years after transplant (49.1% vs 14.2% for the standard drug combination). The risk of serious side effects also dropped from 32.4% to 19.7%. The trial's success has immediate implications for clinical practice in the management of blood stem cell transplants. The simplicity and effectiveness of the new treatment, along with reduced toxicity and improved patient outcomes, will become the new standard of care in GVHD prevention for matched sibling transplants. The ALLG BM12 CAST trial's success is particularly important for patients such as Gladys Borgueta, who was diagnosed with Acute Myeloid Leukaemia (AML) and admitted to Auckland Hospital's Motutapu Ward in May 2021. 'Nothing prepares you for an unexpected diagnosis like acute myeloid leukaemia, everything else becomes a blur and your world is turned upside down. Nothing prepares you for the months, weeks in hospital and sometimes in isolation,' said Gladys. ALLG researcher, haematologist Dr Clinton Lewis and colleagues from Auckland Hospital, met with Gladys and suggested the ALLG BM12 trial. 'I knew that the team around me would give me the best care possible. I had however no high expectations just because this was a trial, it could go either way,' Gladys said. Gladys was allocated to the new treatment arm of the BM12 clinical trial and received a stem cell transplant in January 2022. The new drug combination meant that her transplant was successful and she avoided serious side effects such as GVHD. Three years on, Gladys continues to do well after her transplant and is in remission from her leukaemia. 'Without research, I would not have, or for that matter any other patient, benefited from the treatment I got. I feel grateful and blessed to be given a second chance at life.' Auckland Hospital lead investigator, Dr Clinton Lewis, said, 'The results of this exciting study are already changing practice in New Zealand and will continue to improve the lives of cancer patients receiving allogeneic stem cell transplants.' 'Our options for treating Graft versus Host Disease in New Zealand remain very limited compared to other countries, so preventing this complication is incredibly important for our patients.' 'This study shows that we can help our patients live better lives, free of their cancer and GVHD, when we utilise this treatment approach. This sets an improved standard of care in New Zealand', said Dr Lewis. The BM12 CAST trial was funded by the Australian Government's Medical Research Future Fund, the Auckland Medical Research Fund and the Cancer Society of New Zealand.
